JNJ vs MDLN
JNJ: A global healthcare leader spanning pharmaceuticals, medical devices, and consumer health products, with a portfolio spanning acute care, oncology, immunology, cardiovascular, and infectious disease. MDLN: Medline is a global healthcare products and services distributor supplying hospitals, clinics, and other healthcare settings with medical supplies, equipment, and solutions.
Side-by-side fundamentals
| Metric | JNJ | MDLN | Edge |
|---|---|---|---|
| Price as of 2026-07-16 close | $249.97 | $41.11 | |
| Market cap as of 2026-07-17 | $599.2B | $54.0B | |
| P/E as of 2026-07-17 | 28.48 | 55.91 | JNJ lower |
| PEG as of 2026-07-17 | 3.16 | 11.46 | JNJ lower |
| Net margin as of 2026-07-17 | +21.8% | +3.3% | JNJ higher |
| Gross margin as of 2026-07-17 | +68.0% | +25.9% | JNJ higher |
| Operating margin as of 2026-07-17 | +25.9% | +7.1% | JNJ higher |
| ROE as of 2026-07-17 | +26.3% | +6.9% | JNJ higher |
| ROA as of 2026-07-17 | +10.7% | +2.6% | JNJ higher |
| Debt / equity as of 2026-07-17 | 0.68 | 1.12 | JNJ lower |
| Revenue growth (YoY) as of 2026-07-17 | +7.9% | +10.7% | MDLN higher |
| Revenue CAGR (3y) SEC XBRL | +6.2% | +10.6% | MDLN higher |
| Dividend yield as of 2026-07-17 | +2.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-17 | 0.23 | 1.12 | |
| 1-year return as of 2026-07-16 close | +51.7% | -2.1% | JNJ higher |
Fundamentals: Finnhub, as of 2026-07-17. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-16.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.